From the CEO

Reimbursement Precipitating Shortages

January 02, 2024

GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.

The Dislocation of Progress

December 02, 2023

Pharmaceuticals are entering a transition into a far more complex era of patient therapies, and patient segmentation.

Capitalizing on Success

November 02, 2023

Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.

Renewed Hope for Alzheimer’s

September 28, 2023

It has been a long wait, but for Alzheimer’s at least, this is the beginning of renewed hope.

Supply Chain Securities

August 02, 2023

Mapping America’s Pharmaceutical Supply (MAPS) Act aims to establish a database including key information about critical drugs so supply chain weaknesses can be identified.

Drug Pricing’s Static Changes

July 02, 2023

The debate surrounding drug pricing changes rages on.

Governance of Future Pandemics

June 02, 2023

COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.

Young Pups and Leopards

May 02, 2023

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

Who’s Got Game?

April 02, 2023

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.

Subsurface Currents

March 02, 2023

That wave beginning to crash over PhRMA’s gunwales may well emanate from a startup mindset, rather than Big Pharma or government policy pundits.